Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026)
Revolution Medicines' quarterly Income from Continuing Operations came in at 453816000.0 in Q1 2026, down 112.64% year-on-year from 3589223075.01 in Q1 2025, and down 159.21% quarter-over-quarter from 766409000.0 in Q4 2025.
Revolution Medicines has reported Income from Continuing Operations for 8 years, with the latest figure at 453816000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 112.64% year-over-year to 453816000.0; the trailing twelve-month figure through Mar 2026 stood at 240400000.0 (up 65.53% YoY), and the FY2024 full-year result was 600043000.0, down 36.31% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 453816000.0, down from 766409000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 766409000.0 in Q4 2025, with the low at 453816000.0 in Q1 2026.
- Average Income from Continuing Operations over 5 years is 102517588.24, with a median of 116003000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations plunged 192.58% in 2023 and soared 494.0% in 2025.
- Tracing RVMD's Income from Continuing Operations over 5 years: stood at 56527000.0 in 2022, then plunged by 192.58% to 165385000.0 in 2023, then declined by 17.62% to 194519000.0 in 2024, then soared by 494.0% to 766409000.0 in 2025, then slumped by 159.21% to 453816000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 453816000.0 (Q1 2026), 766409000.0 (Q4 2025), and 305206000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | 766.41 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -165.39 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
| Jun 30, 2021 | -44.30 Mn |
| Mar 31, 2021 | -37.18 Mn |
| Dec 31, 2020 | -34.20 Mn |
| Sep 30, 2020 | -27.22 Mn |
| Jun 30, 2020 | -27.22 Mn |
| Mar 31, 2020 | -19.52 Mn |
| Dec 31, 2019 | -18.97 Mn |
| Sep 30, 2019 | -12.82 Mn |
| Jun 30, 2019 | -10.12 Mn |
| Mar 31, 2019 | -10.13 Mn |